TITLE

The Working After Cancer Study (WACS): a population-based study of middle-aged workers diagnosed with colorectal cancer and their return to work experiences

PUB. DATE
January 2011
SOURCE
BMC Public Health;2011, Vol. 11 Issue 1, p604
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the study conducted to examine the middle-aged workers diagnosed with colorectal cancer and their experiences after returning to work. It identifies the barriers to work resumption, and the limitations on workforce participation. Further it evaluates the influence of these factors on their health. It focuses on the mechanisms people use to continue their working and how the existing workplace support structures.
ACCESSION #
65252667

 

Related Articles

  • Cancer survivorship and work: Symptoms, supervisor response, co-worker disclosure and work adjustment. Pryce, Joanna; Munir, Fehmidah; Haslam, Cheryl // Journal of Occupational Rehabilitation;Mar2007, Vol. 17 Issue 1, p83 

    Introduction: Recent improvements in cancer treatment have not only increased cancer survivorship but also peoples’ ability to work during and following treatment. However, the impact that both diagnosis and treatment has on cancer survivors’ ability to fully engage in paid work is...

  • Continuing Medical Education Questions: July 2011. DeVault, Kenneth R.; Carey, Emily; Hanouneh, Ibrahim; Kane, Saul; Navaneethan, Udayakumar // American Journal of Gastroenterology;Jul2011, Vol. 106 Issue 7, p1207 

    A quiz concerning colonoscopy of elderly patients with colorectal cancer is presented.

  • The Prognostic Significance of Chromosome Abnormalities in Colon Tumors. Lubs, Herbert A.; Kotler, Stuart // Annals of Internal Medicine;Aug67, Vol. 67 Issue 2, p328 

    Provides information on a study that examined the clinical-cytogenetic correlations in patients with colon tumors. Methodology of the study; Results and discussion on the study.

  • Influence of stage at diagnosis on survival differences for rectal cancer in three European populations. Monnet, E; Faivre, J; Raymond, L; Garau, I // British Journal of Cancer;10/1/99, Vol. 81 Issue 3, p463 

    Important differences have recently been highlighted between European countries in the survival of colorectal cancer patients. As data on stage at diagnosis were available for rectal cancers in three European population-based registries (Geneva Switzerland; Côte d'Or, France; Mallorca,...

  • A cohort study of dietary iron and heme iron intake and risk of colorectal cancer in women. Kabat, G. C.; Miller, A. B.; Jain, M.; Rohan, T. E. // British Journal of Cancer;12/3/2007, Vol. 97 Issue 11, p1600 

    A correction to the article "A cohort study of dietary iron and heme iron intake and risk of colorectal cancer in women" that was published in the previous issue is presented.

  • Letter to the Editor: Worse prognosis caused by anti-EGFR treatment in advanced colorectal cancer patients with KRAS mutation. Yin, Peihao; Qiu, Yanyan; Li, Qi // International Journal of Colorectal Disease;May2013, Vol. 28 Issue 5, p733 

    A letter to the editor is presented in response to the article "Worse prognosis caused by anti-EGFR treatment in advanced colorectal cancer patients with KRAS mutation," by Peihao Yin, Yanyan Qiu and Qi Li, published in the previous issue of the periodical.

  • QuickStats.  // MMWR: Morbidity & Mortality Weekly Report;3/27/2015, Vol. 64 Issue 11, p310 

    A chart is presented that shows the mortality rates of U.S. people with colorectal cancer from 1999 to 2013.

  • Ziv-aflibercept yields encouraging results in metastatic colorectal cancer.  // Hem/Onc Today;11/10/2012, Vol. 13 Issue 21, p26 

    The article reports on a study by Doctor Eric Van Cutsem, head of digestive oncology and professor of medicine at University Hospital Gasthuisberg in Leuven, Belgium, stating that the addition of ziv-aflibercept to infusional FOLFIRI improved survival in metastatic colorectal cancer patients.

  • Adverse Reaction Research.  // Reactions Weekly;3/13/2010, Issue 1292, p3 

    The article focuses on a study which examined the use of homozygous UGT1A1*28 genotype to predict grade 3 4 treatment-induced neutropenia in colorectal cancer patients receiving irinotecan.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics